Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8%

Wall Street indices surged, with the Dow up 2.87% to 53,275.11. Volatility fell, with the VIX dropping to 17.08. Commodities saw mixed results: gold and silver rose, while oil fell 7.44%. Amgen (AMGN) reported 8% revenue growth, Thomson Reuters (TRI) saw 10% revenue growth, and Agnico Eagle (AEM) reported strong gold production. CPKC (CP) and Loews (L) also reported earnings.

Original reporting
Published Nov 4, 2026, 6:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 7:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8% — source image
Decision brief

The 30-second read

$AMGNBullishLow
01

Why it matters

Earnings releases drive sector-specific moves; strong biotech and mining results add to bullish sentiment, while weaker transportation and insurance earnings introduce caution.

02

Market read

Earnings data for five major companies provide actionable insight for sector allocation and stock‑specific positioning in a market rally environment.

03

What to watch

Currency effects on Canadian miners and potential supply‑chain constraints for Amgen could temper upside.

Relevance 4/10Novelty 4/10Timing: same-day release

Background

The article is a market commentary summarizing Q3 earnings for several large caps amid a broad rally, with the Dow up 2.87% and VIX falling.

Company-level read

Ticker impact

$AMGNBullishMedium confidence
Context

Amgen reported Q3 revenue up 8% to $10.4B and GAAP EPS $7.08, beating expectations.

Expected impact

likely upside as investors price in better-than-expected earnings

Evidence & confidence

Revenue and EPS both exceeded consensus, supporting a bullish short-term move.

$TRINeutralMedium confidence
Context

Thomson Reuters posted Q3 revenue up 10% to $1.833B, but EPS fell to $0.78 after a stake sale.

Expected impact

moderate pressure as earnings miss may weigh on the stock

Evidence & confidence

Revenue beat but EPS miss creates uncertainty about near‑term direction.

$AEMBullishMedium confidence
Context

Agnico Eagle reported Q3 net income $1.353B, cash balance $3.613B and paid a dividend.

Expected impact

potential upside as investors reward solid earnings and dividend

Evidence & confidence

Robust earnings and cash flow support a favorable short‑term reaction.

$LBearishMedium confidence
Context

Loews reported Q3 net income $306M, down from $504M a year earlier, with share repurchase activity.

Expected impact

likely pressure as profit drop outweighs repurchase benefit

Evidence & confidence

Significant earnings drop suggests downside risk despite buyback.

Market effects

Broad earnings beat in biotech and mining supports sector optimism; mixed results in information services and transportation temper overall market tone.

U.S. and Canadian markets likely see modest gains from strong earnings, offset by weaker performers.

Contributes to overall market rally driven by lower VIX and commodity price moves.

Counterpoint

Investors may focus on cost pressures at CPK and earnings decline at Loews, betting on a short‑term pullback despite headline rally.

Key entities

  • Amgen

    Biopharma with 8% revenue growth and EPS beat.

  • Thomson Reuters

    Information services firm with mixed earnings.

  • Agnico Eagle

    Gold miner delivering strong profit and dividend.

  • Canadian Pacific Kansas City

    Railroad with revenue growth but higher operating ratio.

  • Loews Corporation

    Diversified holding with earnings decline.

Related articles

$ITMed

Barclays downgrades Gartner, flags AI risks for information services stocks

Barclays downgraded Gartner (NYSE: IT) to Underweight, raising its price target to $185. The bank cited concerns about AI disrupting information services companies like Gartner, Thomson Reuters (NYSE: TRI), and FactSet (NYSE: FDS). Despite recent rallies, Barclays remains cautious due to slowing growth and exposure to research models. It maintained mixed ratings on other sector players.

$AMGNMed

Freedom Broker downgrades Amgen stock rating on valuation despite raising price target

Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.

$AMGNLow

FDA Approval for AMJEVITA issued to AMGEN INC

The FDA approved a label update for Amgen's AMJEVITA (adalimumab-atto) on 11/05/2026, according to the company. The approval covers the 20 mg/0.4 mL and 40 mg/0.8 mL injectable products, but no new indication was disclosed. This is a routine regulatory update for an already approved product.